Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison

被引：0
作者：
Simone Biscaglia
Gianluca Campo
Matteo Tebaldi
Carlo Tumscitz
Rita Pavasini
Luca Fileti
Gioel G. Secco
Carlo Di Mario
Roberto Ferrari
机构：
[1] Azienda Ospedaliera Universitaria S.Anna,Cardiovascular Institute
[2] LTTA Centre,Interventional Cardiology
[3] Santi Antonio e Biagio e Cesare Arrigo Hospital,NIHR Cardiovascular Biomedical Research Unit
[4] Royal Brompton and Harefield NHS Foundation Trust,Maria Cecilia Hospital, GVM Care & Research
[5] E.S.: Health Science Foundation,undefined
来源：
The International Journal of Cardiovascular Imaging | 2016年 / 32卷
关键词：
Enhanced stent visualization system; Bioresorbable vascular scaffold; Overlap; Optical coherence tomography; Stacked struts;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
To assess if enhanced stent visualization (ESV)-guided implantation of overlapping bioresorbable vascular scaffold (BVS) is superior to angiography alone-guided implantation in the reduction of overlap length. WOLFIE is a two-centre prospective open study enrolling 30 patients treated with implantation of at least two overlapping BVS. In the first centre (London), BVS implantation was guided by conventional angiography, while in the second centre (Ferrara), an ESV system was systematically employed. The primary endpoint of the study was overlap length. Secondary endpoints were: stacked struts number, area, thickness, and amount of clusters. In the ESV-guided group, overlap length was significantly lower compared to angiography-guided group [0.9 (0.6–1.8) vs. 2.2 (1.3–3.2) mm, p = 0.02]. Similarly, all secondary endpoints were significantly reduced. ESV-guided implantation of overlapping BVS is safe and effective in minimizing both overlap length and number of stacked struts.
引用
收藏
页码：211 / 223
页数：12
相关论文
共 62 条
  • [1] Serruys PW(2015)A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial Lancet 385 43-54
  • [2] Chevalier B(2014)ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance JACC Cardiovasc Interv 7 741-750
  • [3] Dudek D(2014)Current status of bioresorbable scaffolds in the treatment of coronary artery disease J Am Coll Cardiol 64 2541-2551
  • [4] Mattesini A(2015)Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective EuroIntervention 11 45-52
  • [5] Secco GG(2015)Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : a position statement on the use of bioresorbable vascular scaffolds in the Netherlands Neth Heart J 23 161-165
  • [6] Dall’Ara G(2013)Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice JACC Cardiovasc Interv 6 523-532
  • [7] Ghione M(2014)Optical coherence tomography evaluation of overlapping everolimus-eluting bioresorbable vascular scaffold implantation guided by enhanced stent visualization system Int J Cardiol 182C 1-3
  • [8] Wiebe J(2013)Clinical applications of a new Enhanced Stent Imaging technology Catheter Cardiovasc Interv 82 1115-1122
  • [9] Nef HM(2014)ESC/EACTS guidelines on myocardial revascularization Eur Heart J 35 2541-2619
  • [10] Hamm CW(2014)Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb everolimus-eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with De Novo native coronary artery lesions) JACC Cardiovasc Interv 7 1400-1411
1234567